Table 1.
Demographic, ophthalmic characteristics, and serum UA levels of PACG.
| Factors | PACG (n = 64) | Progressing group (n = 32) | Nonprogressing group (n = 32) | P value∗ |
|---|---|---|---|---|
| Age, mean (SD) (years) | 58.30 (15.24) | 59.81 (15.19) | 58.09 (15.27) | 0.657 |
| Sex, male/female | 22/42 | 12/20 | 10/22 | 0.599 |
| BMI, mean (SD) (kg/m2) | 23.96 (3.24) | 23.83 (3.16) | 24.19 (3.46) | 0.720 |
| SBP, mean (SD) (mmHg) | 129.29 (15.13) | 127.94 (14.68) | 131.61 (16.04) | 0.418 |
| DBP, mean (SD) (mmHg) | 75.73 (10.78) | 78.42 (9.42) | 71.11 (11.66) | 0.021 |
| Diabetes, yes/no | 8/56 | 5/27 | 3/29 | 0.708 |
| Hypertension, yes/no | 10/54 | 6/26 | 4/28 | 0.491 |
| Baseline IOP, mean (SD) (mmHg) | 31.12 (9.13) | 32.17 (8.59) | 30.10 (9.64) | 0.372 |
| Baseline VCDR, mean (SD) | 0.60 (0.22) | 0.59 (0.21) | 0.64 (0.26) | 0.449 |
| Baseline CCT, mean (SD) (μm) | 550.47 (42.33) | 554.10 (43.72) | 542.08 (39.30) | 0.399 |
| Baseline ACD, mean (SD) (mm) | 2.20 (0.76) | 2.19 (0.78) | 2.24 (0.74) | 0.851 |
| Baseline AL, mean (SD) (mm) | 22.87 (1.43) | 23.22 (1.51) | 22.18 (0.98) | 0.025 |
| Baseline MD, mean (SD) (dB) | 12.98 (7.93) | 12.28 (8.73) | 13.52 (7.35) | 0.564 |
| Baseline MS, mean (SD) (dB) | 14.73 (8.18) | 15.30 (9.16) | 14.29 (7.43) | 0.650 |
| Pretreat UA, mean (SD) (mmol/l) | 0.286 (0.075) | 0.258 (0.069) | 0.314 (0.069) | 0.002 |
| Pretreat UA (male), mean (SD) (mmol/l) | 0.347 (0.061) | 0.308 (0.043) | 0.394 (0.044) | <0.001 |
| Pretreat UA (female), mean (SD) (mmol/l) | 0.254 (0.060) | 0.228 (0.065) | 0.278 (0.043) | 0.007 |
| Follow-up UA, mean (SD) (mmol/l) | 0.286 (0.074) | 0.266 (0.075) | 0.305 (0.069) | 0.033 |
| Follow-up UA (male), mean (SD) (mmol/l) | 0.345 (0.062) | 0.314 (0.061) | 0.381 (0.040) | 0.008 |
| Follow-up UA (female), mean (SD) (mmol/l) | 0.255 (0.061) | 0.237 (0.069) | 0.271 (0.049) | 0.071 |
| Follow-up IOP, mean (SD) (mmHg) | 21.99 (8.63) | 29.30 (5.05) | 14.90 (4.35) | <0.001 |
| Follow-up MD, mean (SD) (dB) | 13.94 (7.32) | 14.00 (8.20) | 13.89 (6.69) | 0.956 |
| Duration of follow-up, (range) (month) | 12.77 (3~28) | 6.16 (3~12) | 20.91 (12~28) | <0.001 |
| Treatment (% yes) | 100 | 100 | 100 | 1.00 |
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; IOP: intraocular pressure; VCDR: vertical cup-disc ratio; CCT: central corneal thickness; ACD: anterior chamber depth; AL: axial length; MD: visual field mean deviation; MS: visual field mean sensitivity; SD: standard deviation; UA: uric acid. ∗Independent Student's t-test, Fisher exact test, and x2 tests were used for comparison of patient characteristics between the progressing group and nonprogressing group.